Vaccine Development and Production

Overview & Ideals - Blueprinting Immunity

• Vaccine: Agent providing active acquired immunity against a specific disease.
• Immunity:
  • Active: Own antibodies produced (post-vaccine/infection).
  • Passive: Ready-made antibodies transferred (maternal/antitoxin).
• Herd Immunity: Indirect protection for unvaccinated when a high proportion of population is immune.
• Goals: Disease prevention, control, eradication; individual & community protection.
• Ideal Vaccine (📌 SHE IS CHeap):
  • Safe (no/minimal harm)
  • Humoral & Cellular immunity (strong response)
  • Effective (high protection)
  • Inexpensive (affordable)
  • Stable (long shelf-life)
  • Convenient (single dose, easy admin)
• Development Pipeline: Exploratory → Pre-clinical → Clinical Trials (I-III) → Regulatory Review → Manufacturing → Post-marketing Surveillance (IV).

⭐ Adjuvants (e.g., Alum) are added to vaccines to boost immunogenicity by enhancing the host immune response.

Clinical Trial Phases - Testing the Shield

Vaccines undergo rigorous testing, starting with:

• Pre-clinical Studies: In vitro assays and in vivo animal models establish initial safety profiles, immunogenicity, and potential efficacy through dose-ranging and challenge studies.

Clinical trials then proceed in phases:

Vaccine Types & Platforms - Crafting the Armor

Vaccines use varied antigen forms. Production: attenuation (live), inactivation (killed), recombinant tech (subunit/mRNA). 📌 Romance In Brazil Makes My Tummy Yellow (Rotavirus, Influenza-nasal, BCG, MMR, Typhoid-oral, Yellow Fever).

• Live-attenuated: Weakened. BCG, MMR, OPV, Rotavirus, Varicella. Strong immunity (IgA, CMI). Risk: Reversion, CI in immunocompromised.
• Inactivated: Killed. IPV, Rabies, Hep A, Covaxin, wP; Influenza (fractional). Safe. Weaker immunity, boosters.
• Subunit: Specific antigens.
  • Protein: Hep B, aP. Polysaccharide: PPSV23, Typhoid Vi. Conjugate: Hib, PCV13, Meningococcal.
  • Fewer side effects. Adjuvants often needed.
• Toxoid: Inactivated toxins. Tetanus, Diphtheria. Targets toxin.
• Newer:
  • Viral Vector (harmless virus): Covishield, Sputnik V.
  • mRNA (genetic code in LNP): Pfizer, Moderna. DNA (conceptual).
  • Rapid development. Storage issues (mRNA).

⭐ Conjugate vaccines convert T-independent polysaccharide antigens into T-dependent antigens, enabling immune response in infants <2 years and memory.

Quality & Regulation - Guardian Checkpoints

• Key Quality Control (QC) Tests:
  • Identity: Confirms correct immunogen.
  • Purity: Free from contaminants.
  • Potency: Measures immunogenic strength/activity.
  • Sterility: Absence of microbial contamination.
  • Safety: General safety, pyrogenicity/endotoxin, abnormal toxicity tests.
• Stability Testing: Determines shelf-life under varied conditions.
• Good Manufacturing Practices (GMP): Ensure consistent production, quality, safety.
• Regulatory Oversight:
  • National Regulatory Authorities (NRAs) e.g., CDSCO (India).
  • WHO Prequalification (PQ) for UN procurement.
• Lot Consistency & Release: NRA reviews/tests each batch pre-market.

• AEFI Surveillance: Monitoring & reporting Adverse Events Following Immunization.

⭐ The critical importance of maintaining the 'cold chain' (temperature-controlled supply chain) for vaccine efficacy, especially for temperature-sensitive vaccines like live attenuated and mRNA vaccines.

High‑Yield Points - ⚡ Biggest Takeaways

• Clinical trials progress through Phase I (safety), II (efficacy/dosage), III (large-scale efficacy), and IV (post-marketing).
• Maintaining the cold chain (+2°C to +8°C) is essential for vaccine potency.
• Adjuvants (e.g., Alum) boost immunogenicity; preservatives (e.g., Thimerosal) ensure sterility.
• Killed vaccines use inactivation (formalin); live attenuated vaccines use attenuation (serial passage).
• Recombinant DNA technology produces vaccines like Hepatitis B (HBsAg).
• Good Manufacturing Practices (GMP) ensure vaccine quality and safety during production.